US 12,214,048 B2
Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
Madiha Derouazi, Grand-Saconnex (CH); and Elodie Belnoue, Geneva (CH)
Assigned to AMAL THERAPEUTICS SA, Geneva (CH)
Filed by AMAL THERAPEUTICS SA, Geneva (CH)
Filed on Jan. 5, 2022, as Appl. No. 17/569,261.
Application 17/569,261 is a continuation of application No. 16/084,170, abandoned, previously published as PCT/EP2017/056034, filed on Mar. 14, 2017.
Claims priority of application No. PCT/EP2016/000472 (WO), filed on Mar. 16, 2016; and application No. PCT/EP2016/070264 (WO), filed on Aug. 26, 2016.
Prior Publication US 2022/0118102 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/06 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/42 (2017.01); A61K 47/64 (2017.01); A61K 47/66 (2017.01); A61P 35/00 (2006.01); C07K 2/00 (2006.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 14/475 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 15/62 (2006.01)
CPC A61K 47/66 (2017.08) [A61K 38/17 (2013.01); A61K 38/18 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 39/464416 (2023.05); A61K 47/42 (2013.01); A61K 47/64 (2017.08); A61K 47/642 (2017.08); A61K 47/6425 (2017.08); A61P 35/00 (2018.01); C07K 2/00 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/475 (2013.01); C07K 16/2818 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C07K 19/00 (2013.01); C12N 15/625 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55572 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2319/10 (2013.01); C07K 2319/40 (2013.01)] 32 Claims
 
1. A combination comprising:
(i) an immune checkpoint modulator, and
(ii) a complex comprising:
a) a cell penetrating peptide;
b) at least one antigen or antigenic epitope; and
c) at least one TLR peptide agonist, wherein the TLR peptide agonist is a TLR2 or TLR4 peptide agonist, and
wherein components a)-c) are covalently linked.